Skip to main content
. 2023 Oct 2;29(23):4797–4807. doi: 10.1158/1078-0432.CCR-23-1860

Figure 1.

Figure 1. ctDNA detection for prognosis assessment in patients treated with NAC. A, Kaplan–Meier survival analysis of RFS and plasma ctDNA status before NAC. B, Kaplan–Meier survival analysis of OS and plasma ctDNA status before NAC. C, Association between plasma ctDNA status before NAC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. D, Kaplan–Meier survival analysis of RFS and plasma ctDNA status before RC. E, Kaplan–Meier survival analysis of OS and plasma ctDNA status before RC. F, Association between plasma ctDNA status before RC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. G, Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status after RC. H, Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status after RC. I, Association between accumulated plasma ctDNA status after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed. No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. J, Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status within 1 year after RC. K, Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status within 1 year after RC. L, Association between accumulated plasma ctDNA status within 1 year after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed (the last plasma sample within the 1-year time period after RC). No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. HRs, associated 95% CIs, and P values are displayed on each Kaplan–Meier plot (Cox regression analysis). Significant statistical difference between ctDNA status and recurrence was determined using Fisher exact test.

ctDNA detection for prognosis assessment in patients treated with NAC. A, Kaplan–Meier survival analysis of RFS and plasma ctDNA status before NAC. B, Kaplan–Meier survival analysis of OS and plasma ctDNA status before NAC. C, Association between plasma ctDNA status before NAC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. D, Kaplan–Meier survival analysis of RFS and plasma ctDNA status before RC. E, Kaplan–Meier survival analysis of OS and plasma ctDNA status before RC. F, Association between plasma ctDNA status before RC and recurrence status within 1 year after RC including only patients with at least 1 year of follow-up after RC. G, Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status after RC. H, Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status after RC. I, Association between accumulated plasma ctDNA status after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed. No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. J, Kaplan–Meier survival analysis of RFS and accumulated plasma ctDNA status within 1 year after RC. K, Kaplan–Meier survival analysis of OS and accumulated plasma ctDNA status within 1 year after RC. L, Association between accumulated plasma ctDNA status within 1 year after RC and recurrence. Recurrence was defined as detection of clinical recurrence from radiographic imaging results up to 2 years after the last plasma sample was analyzed (the last plasma sample within the 1-year time period after RC). No recurrence was defined as absence of clinical recurrence during the surveillance period of up to 2 years after the last plasma sample was analyzed, including only patients with at least 2 years of follow-up after RC. HRs, associated 95% CIs, and P values are displayed on each Kaplan–Meier plot (Cox regression analysis). Significant statistical difference between ctDNA status and recurrence was determined using Fisher exact test.